Medifast INC (MED) — SEC Filings

Q: What are the key financial highlights for Medifast INC?

Key financial highlights for Medifast INC are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Medifast INC?

Key executives at Medifast INC are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Medifast INC stock?

Risk factors for Medifast INC (MED) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Medifast INC?

Forward-looking statements and predictions from Medifast INC are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Medifast INC. Recent ARS filing on Apr 6, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Medifast INC on SEC EDGAR

Overview

Medifast INC (MED) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 6, 2026: Medifast Inc. filed its Annual Report to Security Holders (ARS) on April 6, 2026, for the period ending December 31, 2025. The company, headquartered in Baltimore, MD, operates in the Miscellaneous Food Preparations & Kindred Products sector. This filing provides a comprehensive overview of the comp

Sentiment Summary

Across 19 filings, the sentiment breakdown is: 2 bearish, 17 neutral. The dominant filing sentiment for Medifast INC is neutral.

Filing Type Overview

Medifast INC (MED) has filed 1 ARS, 6 10-Q, 2 8-K, 2 DEF 14A, 2 10-K, 5 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (19)

Medifast Files 2025 Annual Report — ARS · Apr 6, 2026 Risk: low
Medifast Inc. filed its Annual Report to Security Holders (ARS) on April 6, 2026, for the period ending December 31, 2025. The company, headquartered in Baltimo
Medifast Plunges to Q3 Loss Amid 36% Revenue Drop — 10-Q · Nov 3, 2025 Risk: high
Medifast, Inc. (MED) reported a significant decline in financial performance for the three and nine months ended September 30, 2025. Revenue decreased by 36.2%
Medifast Q2 Revenue Plunges 25% Amidst Stiff Competition — 10-Q · Aug 4, 2025 Risk: high
MEDIFAST INC reported a significant decline in financial performance for the second quarter ended June 30, 2025. Revenue decreased to $170.0 million, a substant
Medifast Reports Director Elections & Officer Changes — 8-K · Jun 20, 2025 Risk: medium
On June 18, 2025, Medifast, Inc. filed an 8-K report detailing several key events. The company announced the election of new directors, changes in certain offic
Medifast DEF 14A: Executive Equity Awards Detailed — DEF 14A · Apr 29, 2025 Risk: low
Medifast Inc. filed a DEF 14A on April 29, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, including equity award
Medifast Files Q1 2025 10-Q Report — 10-Q · Apr 28, 2025 Risk: medium
Medifast Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 202
Medifast Inc. Files 2024 Annual Report — 10-K · Feb 18, 2025 Risk: medium
Medifast Inc. filed its 10-K for the fiscal year ending December 31, 2024, on February 18, 2025. The filing provides a comprehensive overview of the company's f
Medifast Inc. Files Q3 2024 10-Q Report — 10-Q · Nov 4, 2024 Risk: medium
Medifast Inc. reported its third-quarter results for the period ending September 30, 2024. The company's financial performance for this quarter and the year-to-
Medifast Inc. Files Q2 2024 10-Q Report — 10-Q · Aug 5, 2024 Risk: medium
Medifast Inc. reported its second quarter results for the period ending June 30, 2024. The company's financial performance for this quarter and the preceding si
SC 13G/A Filing — SC 13G/A · Jul 10, 2024
SC 13G/A Filing — SC 13G/A · Jul 8, 2024
SC 13G Filing — SC 13G · Jul 1, 2024
Medifast Announces Board Changes and Executive Compensation Updates — 8-K · Jun 21, 2024 Risk: medium
On June 19, 2024, MEDIFAST, INC. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the election of
Medifast Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · Apr 29, 2024 Risk: low
MEDIFAST INC (MED) filed a Quarterly Report (10-Q) with the SEC on April 29, 2024. Medifast Inc. filed its quarterly report (10-Q) for the period ending March 3
MEDIFAST INC. DEF 14A Filing — DEF 14A · Apr 26, 2024 Risk: low
MEDIFAST INC (MED) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. This filing is a Definitive Proxy Statement (DEF 14A) for MEDIFAST INC. The
Medifast Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 20, 2024 Risk: medium
MEDIFAST INC (MED) filed a Annual Report (10-K) with the SEC on February 20, 2024. Medifast Inc. filed its 10-K report for the fiscal year ending December 31, 2
Vanguard Boosts Medifast Stake to 25.0% as of Dec 29, 2023 — SC 13G/A · Feb 13, 2024 Risk: low
The Vanguard Group, a major investment firm, filed an amended SC 13G/A on February 13, 2024, disclosing its ownership of Medifast Inc. common stock as of Decemb
Renaissance Tech Amends Medifast Stake (SC 13G/A) — SC 13G/A · Feb 13, 2024 Risk: low
Renaissance Technologies LLC, a prominent investment firm, filed an amended SC 13G/A on February 13, 2024, indicating a change in their ownership of Medifast, I
BlackRock Amends MEDIFAST Stake, Signals Passive Investment Update — SC 13G/A · Jan 22, 2024
BlackRock Inc. filed an amended SC 13G/A on January 22, 2024, indicating a change in their ownership of MEDIFAST INC common stock as of December 31, 2023. This

Risk Profile

Risk Assessment: Of MED's 15 recent filings, 2 were flagged as high-risk, 7 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Medifast INC's most recent 10-Q filing (Nov 3, 2025):

Revenue: $89.4M
Net Income: -$2.3M
EPS: -$0.21

Industry Context

The health and wellness sector, particularly direct-to-consumer models like Medifast, faces intense competition and evolving consumer preferences. Companies are increasingly focused on digital engagement and personalized solutions. The industry is also sensitive to economic conditions, as discretionary spending on health products can fluctuate.

Top Tags

10-Q (4) · financials (4) · earnings (3) · institutional-ownership (3) · amendment (3) · annual-report (2) · sec-filing (2) · Weight Management (2) · Direct Selling (2) · Revenue Decline (2)

Key Numbers

Fiscal Year End: 2025 — Reporting period for the annual report.
Document Size (ARS PDF): 24549498 — Size of the main annual report document.
Revenue for Q3 2025: $89.4M — down 36.2% from $140.2M in Q3 2024
Net loss for Q3 2025: $(2.26M) — compared to net income of $1.13M in Q3 2024
Diluted EPS for Q3 2025: $(0.21) — compared to $0.10 in Q3 2024
Revenue for nine months ended Sep 30, 2025: $310.7M — down 35.7% from $483.5M in the prior year
Net loss for nine months ended Sep 30, 2025: $(0.55M) — compared to net income of $1.29M in the prior year
Advertising expense for Q3 2025: $0.7M — down from $4.6M in Q3 2024
Inventories, net as of Sep 30, 2025: $23.2M — down from $42.4M as of Dec 31, 2024
Shares outstanding as of Oct 27, 2025: 10,991,273 — stable compared to prior periods
Q2 2025 Revenue: $170.0M — Decreased 25.0% from $226.7M in Q2 2024
Q2 2025 Net Income: $15.3M — Decreased 40.0% from $25.5M in Q2 2024
Revenue Decline: 25.0% — Year-over-year decrease in Q2 2025 revenue
Net Income Decline: 40.0% — Year-over-year decrease in Q2 2025 net income
Period End Date: 2025-06-30 — End of the second fiscal quarter

Forward-Looking Statements

{"claim":"Vanguard will maintain a significant stake in Medifast Inc. for the foreseeable future.","entity":"The Vanguard Group","targetDate":"December 29, 2024","confidence":"high"}
{"claim":"Medifast Inc.'s stock price will likely show less volatility due to Vanguard's large, stable institutional ownership.","entity":"Medifast Inc.","targetDate":"June 30, 2024","confidence":"medium"}
{"claim":"Other quantitative funds may review Renaissance Technologies' updated position in Medifast, potentially leading to similar adjustments in their own portfolios.","entity":"Medifast, Inc.","targetDate":"Q1 2024","confidence":"medium"}

Related Companies

WW · NUTRI

Frequently Asked Questions

What are the latest SEC filings for Medifast INC (MED)?

Medifast INC has 19 recent SEC filings from Jan 2024 to Apr 2026, including 6 10-Q, 5 SC 13G/A, 2 8-K. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of MED filings?

Across 19 filings, the sentiment breakdown is: 2 bearish, 17 neutral. The dominant sentiment is neutral.

Where can I find Medifast INC SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Medifast INC (MED) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Medifast INC?

Key financial highlights from Medifast INC's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for MED?

The investment thesis for MED includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Medifast INC?

Executive information for Medifast INC is extracted from SEC filings as they are enriched with AI analysis.

What are the main risk factors for Medifast INC stock?

Of MED's 15 assessed filings, 2 were flagged high-risk, 7 medium-risk, and 6 low-risk.

What are recent predictions and forward guidance from Medifast INC?

Recent forward-looking statements from Medifast INC include guidance on {"claim":"Vanguard will maintain a significant stake in Medifast Inc. for the foreseeable future.","entity":"The Vanguar and 2 other predictions.